HIVIS

HIVIS (HIV Vaccine Immunogenicity Study) refers to a prime-boost HIV-1 vaccine regimen developed through a collaboration between the Karolinska Institutet, the Swedish Institute for Infectious Disease Control (SMI), and the Muhimbili University of Health and Allied Sciences (MUHAS). The regimen typically consists of a multi-plasmid DNA vaccine (HIV-DNA) as a primer, followed by a recombinant Modified Vaccinia Ankara (MVA) virus vaccine (HIV-MVA) as a boost. The DNA component contains a mixture of plasmids encoding HIV-1 subtypes A, B, and C antigens, including Gag, Pol, Env, and Rev. The MVA boost expresses similar antigens to broaden and strengthen the cellular and humoral immune responses. The regimen has been evaluated in several Phase I and II clinical trials in East Africa, exploring various delivery methods such as intradermal injection with electroporation to enhance immunogenicity.

Other names

HIVIS vaccine regimenHIVIS DNA vaccineHIVIS MVA vaccineHIV Vaccine Immunogenicity Study